Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y₁₂ inhibitors.

ABSTRACT:

Background

Despite the increasing use of potent P2Y₁₂ inhibitors, further atherothrombotic events still impair the prognosis of many acute coronary syndrome (ACS) patients. This may in part be attributable to intact platelet aggregation via the human thrombin receptors protease-activated receptor (PAR)-1 and PAR-4.

Objective

We studied PAR mediated platelet aggregation in ACS patients following percutaneous coronary intervention (PCI) with stent implantation in a cross-sectional study.

Methods

Platelet aggregation to ADP as well as to the PAR-1 agonist SFLLRN and the PAR-4 agonist AYPGKF was assessed by multiple electrode aggregometry in 194 ACS patients on dual antiplatelet therapy with aspirin and either prasugrel (n = 114) or ticagrelor (n = 80) 3 days a

SUBMITTER: Wadowski PP 

PROVIDER: S-EPMC6611376 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature